Table 2.
Overall best confirmed responses
| ALCYONE ITT population15 | East Asian | Japanese | Korean | |||||
|---|---|---|---|---|---|---|---|---|
| D-VMP (n = 350) |
VMP (n = 356) |
D-VMP (n = 47) |
VMP (n = 44) |
D-VMP (n = 24) |
VMP (n = 26) |
D-VMP (n = 23) |
VMP (n = 18) |
|
| Response category, n (%) | ||||||||
| ORR | 318 (90.9) | 263 (73.9) | 44 (93.6) | 35 (79.5) | 23 (95.8) | 24 (92.3) | 21 (91.3) | 11 (61.1) |
| sCR | 63 (18.0) | 25 (7.0) | 16 (34.0) | 6 (13.6) | 12 (50.0) | 5 (19.2) | 4 (17.4) | 1 (5.6) |
| CR | 86 (24.6) | 62 (17.4) | 7 (14.9) | 3 (6.8) | 1 (4.2) | 1 (3.8) | 6 (26.1) | 2 (11.1) |
| VGPR | 100 (28.6) | 90 (25.3) | 15 (31.9) | 14 (31.8) | 6 (25.0) | 10 (38.5) | 9 (39.1) | 4 (22.2) |
| PR | 69 (19.7) | 86 (24.2) | 6 (12.8) | 12 (27.3) | 4 (16.7) | 8 (30.8) | 2 (8.7) | 4 (22.2) |
| SD | 20 (5.7) | 76 (21.3) | 2 (4.3) | 7 (15.9) | 1 (4.2) | 2 (7.7) | 1 (4.3) | 5 (27.8) |
| PD | 0 | 2 (0.6) | 0 | 0 | 0 | 0 | 0 | 0 |
| NE | 12 (3.4) | 15 (4.2) | 1 (2.1) | 2 (4.5) | 0 | 0 | 1 (4.3) | 2 (11.1) |
| CR or better | 149 (42.6) | 87 (24.4) | 23 (48.9) | 9 (20.5) | 13 (54.2) | 6 (23.1) | 10 (43.5) | 3 (16.7) |
| VGPR or better | 249 (71.1) | 177 (49.7) | 38 (80.9) | 23 (52.3) | 19 (79.2) | 16 (61.5) | 19 (82.6) | 7 (38.9) |
ITT intent-to-treat, D-VMP daratumumab/bortezomib/melphalan/prednisone, VMP bortezomib/melphalan/prednisone, ORR overall response rate, sCR stringent complete response, CR complete response, VGPR very good partial response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable